Hypofractionated radiation therapy for prostate cancer: Risks and potential benefits in a fiscally conservative health care system

ONCOLOGY (United States)

Volumn 26, Issue 6, 2012, Pages

  Aneja, Sanjay ^a   Pratiwadi, Ramya R ^b   Yu, James B ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER CONTROL; CANCER RADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITY; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG CANCER; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RADIOSENSITIVITY; REVIEW; RISK BENEFIT ANALYSIS; STEREOTACTIC BODY RADIATION THERAPY; THERAPY EFFECT; UROGENITAL TRACT DISEASE;

EID: 84874630310     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Schroder FH. Prostate cancer around the world. An overview. Urol Oncol. 2010;28:663-7.
2. Quon H, Cheung PC, Andrew Loblaw D, et al. Quality of life after hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;83:617-23.
3. Kavanagh BD, Miften M, Rabinovitch RA. Advances in treatment techniques: stereotactic body radiation therapy and the spread of hypofractionation. Cancer J. 2011;17:177-81.
4. Ritter M, Forman J, Kupelian P, et al. Hypo-fractionation for prostate cancer. Cancer J. 2009; 15:1-6.
5. Ritter M. Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer. Semin Radiat Oncol. 2008;18:249-56.
6. Macias V, Biete A. Hypofractionated radiotherapy for localised prostate cancer. Review of clinical trials. Clin Transl Oncol. 2009;11:437-45.
7. McBride SM, Wong DS, Dombrowski JJ, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer. 2011 Dec 13. [Epub ahead of print]
8. US National Institutes of Health. Available from: http://www.clinicaltrials.gov. Accesssed March 12, 2012.
9. Yeoh EE, Botten RJ, Butters J, et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys. 2011;81:1271-8.
10. Pollack A, Walker G, Buyyounouski M, et al. Five-year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2011;81:S1.
11. Kruser TJ, Jarrard DF, Graf AK, et al. Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence. Cancer. 2011;117:2629-36.
12. Wong GW, Palazzi-Churas KL, Jarrard DF, et al. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2008;70:449-55.
13. King CR, Brooks JD, Gill H, Presti JC, Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82:877-82.
14. Boike TP, Lotan Y, Cho LC, et al. Phase I dose-escalation study of stereotactic body radiation therapy for low-and intermediate-risk prostate cancer. J Clin Oncol. 2011;29:2020-6.
15. Arcangeli G, Saracino B, Gomellini S, et al. A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010;78:11-8.
16. Dearnaley D, Syndikus I, Sumo G, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol. 2012;13:43-54.
17. Kwok Y, Yovino S. Update on radiation-based therapies for prostate cancer. Curr Opin Oncol. 2010; 22:257-62.
18. Turaka A, Zhu F, Buyyounouski MK, et al. Conventional versus hypofractionated IMRT: results of late GI and GU toxicity and quality of life from a phase III trial. Int J Radiat Oncol Biol Phys. 2010;78:S67.
19. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250-61.
20. Pardo Y, Guedea F, Aguilo F, et al. Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol. 2010;28:4687-96.
21. Plataniotis GA, Kouvaris JR, Dardoufas C, et al. A short radiotherapy course for locally advanced non-small cell lung cancer (NSCLC): effective palliation and patients convenience. Lung Cancer. 2002;35:203-7.
22. Aneja S, Smith BD, Gross CP, et al. Geographic analysis of the radiation oncology workforce. Int J Radiat Oncol Biol Phys. 2012;82:1723-9.
23. Nguyen PL, Gu X, Lipsitz SR, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol. 2011;29:1517-24.
24. Kavanagh BD, Raben D. Back to the future: a proton pro/con. Oncology (Williston Park). 2011;25:657, 60, 62-3.
25. Lievens Y. Hypofractionated breast radiotherapy: financial and economic consequences. Breast. 2010;19:192-7.
26. Dwyer P, Hickey B, Burmeister E, Burmeister B. Hypofractionated whole-breast radiotherapy: impact on departmental waiting times and cost. J Med Imaging Radiat Oncol. 2010;54:229-34.
27. van den Hout WB, Kramer GW, Noordijk EM, Leer JW. Cost-utility analysis of short-versus long-course palliative radiotherapy in patients with non-small-cell lung cancer. J Natl Cancer Inst. 2006;98:1786-94.
28. Lukka H, Hayter C, Julian JA, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol. 2005; 23:6132-8.
29. van den Hout WB, van der Linden YM, Steenland E, et al. Single-versus multiple-fraction radiotherapy in patients with painful bone metastases: cost-utility analysis based on a randomized trial. J Natl Cancer Inst. 2003;95:222-9.